This Kentucky Senator is Challenging the Federal THC Limit in Hemp – Hemp Grower

Dmytro Sukharevsky | Adobe Stock

The U.S. Department of Agriculture (USDA) had its hands tied when it came to changing the legal tetrahydrocannabinol (THC) limit of 0.3% in its final rule on hemp, which was released Jan. 15 and is set to take effect March 22.

The final rule, which regulates U.S. hemp production under the Agriculture Improvement Act of 2018 (the 2018 Farm Bill), will replace the USDA’s interim final rule (IFR) on hemp, published Oct. 31, 2019. One of the most heated aspects of the IFR was that hemp containing more than 0.3% THC (dubbed “hot hemp”) in state-administered tests is technically considered marijuana (a Schedule 1 controlled substance) and must be disposed of.

After the IFR was released, hundreds of growers and other industry stakeholders opposed the mandated 0.3% THC limit during two separate public comment periods offered by the USDA, with some industry organizers advocating an increase to 1% THC—the concentration threshold for cannabis to have a psychotropic effect or an intoxicating potential, according to the Congressional Research Service’s (CRS) 2019 fact sheet. In fact, Kentucky lawmakers introduced a bill last week that would increase the allowable amount of THC in hemp from 0.3% to 1%.

RELATED: Dr. Ethan Russo Endorses 1% THC Limit for Hemp

“The 2018 Farm Bill, which provides authority to USDA for the domestic production of hemp and provided USDA with a framework of requirements, removed hemp from Schedule I of the Controlled Substances Act, and defined hemp as the plant cannabis sativa L., or any part of that plant, including seeds, derivatives and extracts, with a THC concentration of not more than 0.3% on a dry-weight basis,” a USDA spokesperson told Hemp Grower. “What this means is that the THC concentration limit for hemp was established by the law and is not a requirement that can be changed by regulation but would require congressional action.”

With that in mind, it was no surprise when 0.3% remained the legal limit for hemp in the USDA’s final rule, says Joy Beckerman, principal of Hemp Ace International, which provides professional hemp consulting, legal support and expert services. 

The legal framework of the 0.3% THC limit was laid out in both the 2018 and 2014 farm bills.

“The regulations cannot override what’s written in law,” Beckerman tells Hemp Grower. “In order for a regulation to override what’s written in law, the law needs to change. To ask the USDA to override the U.S. congressional definition of hemp is not something that they had the authority to do.”

Jason Waggoner, the vice president and general manager of Colorado-based EcoGen Biosciences, a leading vertically integrated wholesale CBD manufacturer and supplier of hemp-derived ingredients in the U.S., had a similar take on the USDA’s role in the legal definition of hemp.

“My opinions on that particular level, relative to what the USDA is doing, are probably moot because that’s not their prerogative,” he said. “They’re the regulatory body to enforce the law. So, until such time that that law is revised, I think their hands are probably tied relative to that number.”

While increasing the 0.3% legal limit was out of the USDA’s hands, the final rule did add some stability for hemp industries by providing several improvements based on feedback it received on the interim final rule (IFR), said Eric Steenstra, president of Vote Hemp, an advocacy group based in Washington, D.C.

“I am pleased that USDA listened to feedback from the hemp industry and farmers as they finalized regulations for hemp production,” Steenstra tells Hemp Grower. “The new rules mean less crops will be non-compliant, protecting farmers from crop destruction and losses. This and other helpful provisions make the new hemp rules a significant step in the right direction.”

Some of final rule changes include an expanded harvest window, alternative options for disposing of or remediating hemp, and an increased standard of negligence.

Aside from the legal parameters in the final rule, the 0.3% limit isn’t something that necessarily has any scientific reason to back it up, says Deepank Utkhede, the chief operations officer of Vantage Hemp, a large-scale extraction facility located in Greeley, Colo., which produces a full range of CBD products for customers across the United States.

“I’m an advocate to increasing it, period,” Utkhede says about the legal THC limit for hemp. “The 0.3% was arbitrary. It wasn’t based on any science or data to say, you know, ‘At 0.4%, you’re going to get high.’ It was just a number that was chosen at random by all accounts. So, it’s hard to justify it when there’s no data to support it.”

Beckerman says the genesis of the 0.3% threshold that differentiates between what is considered industrial hemp and marijuana goes back to 1976, when Canadian horticulturalists Ernest Small and Arthur Cronquist published an article in the journal Taxon, entitled “A Practical and Natural Taxonomy for Cannabis.”

In the article, Small and Cronquist said, “It will be noted that we arbitrarily adopt a concentration of 0.3% delta-9 THC (dry-weight basis) in young, vigorous leaves of relatively mature plants as a guide to discriminating two classes of plants.”

Beckerman says the key words in that article are “arbitrarily adopt.” Forty-five years later, lawmakers and public policy institutes, like the CRS, are still referencing Small’s article while shaping the law of the land.  

Future Implications

What are the implications of increasing the allowable amount of THC in hemp?

Specifically, for testing hemp that’s growing in the field, increasing the legal limit would affect both international trade as well as economic stability for farmers, Beckerman says. For example, Canada and the European Union both have legal THC limits of 0.3%.

“That’s the first thing that we need to know and understand as an implication, is that we want to be able to trade internationally,” Beckerman says. “We don’t want to shoot ourselves in the foot by making it so that other countries don’t want anything to do with American hemp because we have the 1% versus their 0.3%. So, we do need to be mindful of that.”

Beckerman says she is an advocate of changing the law to remove decarboxylation testing in the field. This process activates compounds such as THC, which can happen through heat or certain oxidation. In short, that method of testing imposes a “total THC” standard, which includes not only delta-9-THC—the primary intoxicating compound of cannabis—but also tetrahydrocannabinolic acid (THCA), a non-psychoactive compound of the plant that becomes THC when in post-decarboxylation.

While the USDA wrote the requirement to test for total THC into the final rule, the 2018 Farm Bill does not define hemp by total THC levels—only delta-9-THC. That means the USDA is interpreting the 2018 Farm Bill to include total THC.

The majority of farmers wouldn’t “pop hot” if they didn’t have to post-decarboxylate and quantify the THCA in their plants, Beckerman says.

Another concern with changing the law to increase THC’s allowable amount to 1% is massive overproduction of extract varieties, Beckerman says.

That said, if the law is changed to increase the legal THC limit to 1%, then farmers would be encouraged to continue to grow extract varieties, which will not provide them with economic stability, Beckerman says.

“And we need to protect our farmers,” she says. “At the same time, we can’t say, ‘Hey farmers, start growing fiber hemp. Just grow fiber hemp. Stop growing extract hemp.’ Really? Who are they going to sell it to? Where are the fiber processors?”

The future of hemp is not in the extract, but rather in the oil seed and the fiber of the cannabis plant, Beckerman said. But more fiber processors are needed to cater to that marketplace.

“They’re coming, let me tell you,” she said. “We’ve got five ones in the United States that are coming in, and there’ll be more, but, as it sits today, am I going to tell a farmer in the state of Washington [to grow fiber hemp] when the nearest fiber processing plant is in Montana and it hasn’t been built yet? No.”

How to improve mental focus by using CBD — Greenway Magazine – Greenway

Concentration problems are present in all ages. These issues can be caused by different factors: Cognitive and psychological disorders, medical treatment effects, mental overwhelmed situations, and more. These issues can be innate, hereditarian, biological, or just issues obtained during the lifetime. Sometimes it is very easy to solve the problem, nevertheless, in most cases, lack of concentration supposes deeper difficulties. Here are some causes of concentration deficit:

  • Unbalanced diet
  • Sleep disorder
  • Increased caffeine intake
  • Stress

Nevertheless, there is not a certain diagnosis of why, how, and when lack of concentration appeared, therefore there is no 100% reliable treatment for it. In this world of experiments and consumerism, every day, new treatments in the form of drugs or oils, or edible substances appear. New products containing CBD appear in the market and have high positive remarks. CBD containing oils, lotions, natural CBD edibles, and other goods are introduced in the market and have positive resonances. First of all, to understand the effect that these new products have on your body it is decisive to have an idea about what CBD is and how it affects your mental and physical health in general.

CBD: Myth or Verity

CBD stands for cannabidiol. It is derived from the hemp plant. According to a report from the World Health Organization, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential…. To date, there is no evidence of public health-related problems associated with the use of pure CBD.

There is a wrong perception that CBD causes a high. This component of the cannabis plant does not contain psychoactive components in contradiction to THC, with which CBD is very often confused. CBD is widely used to relieve pain, reduce anxiety and depression, prevent heart problems and among these and more positive effects, CBD also helps you to improve your focus.

CBD and Dopamine

Dopamine is a neurotransmitter, responsible for memory and mental awareness. When the levels of dopamine are low the attention and focus of a man decrease. CBD is directly associated with the brain’s dopamine. By using CBD containing oils or organic CBD edibles you reduce the possibility of irregular changes in dopamine levels. CBD also helps to enhance focus.

CBD and Insomnia

To understand the process of how CBD affects to improve our mental focus it is essential to follow the whole process of the effect CBD has on our organism. First of all, by taking CBD-containing products your body is relaxed and you get enough sleep. CBD positively affects insomnia and sleep disorders. As it is known enough sleep and a rested mind have fewer probabilities to be little concentrated or not focused at all. This is on the one hand.

CBD as a Mood Regulator


On the other hand, regulation of mood and energy can also have a positive effect on reducing the lack of focus. CBD has a relaxing effect on the body. CBD containing topicals have a local effect, meanwhile, edibles or vaping have a direct global effect. Relaxing the anxiety helps our brain function faster and come out of the fog.

It is also proven that CBD increases brain cell production. enhances response time and reflex.

CBD and Endocannabinoid system

CBD supports our endocannabinoid system and acts positively for our overall health. It supports our body’s hormonal and immune system functions. While our body is balanced we are productive and efficient.

CBD and Stress

CBD acts against stress as well, by backing away cortisol, a chemical which excess may make our concentration process harder and sometimes even impossible. There is no clear evidence on how CBD reduces and calms stress and anxiety, nonetheless, it is believed that it acts affecting serotonin levels in the brain. Serotonin is a chemical nerve cell producer that sends signals between the nerve cells. It is responsible for your mood, cognition, and memory. It is also responsible for other processes like vomiting. Controlling serotonin levels, our mental relaxed state also controls our concentration levels.   

There are several CBD containing products that can be used for lack of concentration.

  • Pure CBD Oil Tinctures – While containing CBD isolate, it’s excellent for those who are concerned with even a small amount of CBD triggering a positive drug test.
  • Oral Tinctures – Being abroad-spectrum product, meaning that it may induce the entourage effect when taken over a time
  • Full Spectrum CBD Oils -It is suggested to use these tincture once or twice a day for standard relief, or three to four times a day for extreme relief. They also recommend taking the tincture on an empty stomach and allowing the oils to absorb under the tongue for 20-30 seconds before swallowing.

There are many other products containing CBD and many other ways of taking them.

CBD can help to concentrate and focus on the issues and things that seem to be important for you. It does not directly affect the concentration issue but works on improving the issues that are the main causes of concentration decrease. Sometimes an unbelievably simple disorder can cause serious concentration problems. Sometimes these miserable issues are really difficult to deal with. Practice with CBD has shown that it has a calming effect on our body and brain, that it reduces levels of anxiety, and affects our mood positively. Nevertheless, it is always a good decision to consult the doctor before taking any concentration containing CBD.   

Martha Stewart launching line of cannabis products for dogs – New York Post

Lifestyle guru Martha Stewart on Tuesday launched a line of cannabis-infused oil drops and soft-baked chews for dogs, months after the successful release of her cannabidiol (CBD) gummie treats for humans hit shelves in the United States.

Stewart is banking on a nearly one-year partnership with Canada’s Canopy Growth, the world’s top pot producer by market value, and now wants to reach pet owners and tap into a meteoric rise in demand for pot-based products.

Last year, stay at home orders to stem the spread of COVID-19 limited people’s entertainment options and fueled stress and anxiety. Cannabis-infused edibles, like gummies and chocolates, and beverages were among the most highly-sought cannabis products.

CBD, a non-psychoactive compound derived mainly from hemp, is being researched for various medical applications and is widely advertised to have relaxing properties.

Stewart wants to bring those benefits to dogs with CBD oil drops and soft-baked chews, which she claims can help with mental and physical well-being, reduce stress and maintain joint health and movement.

“My dogs are not only my companions, but they are part of my family, and I prioritize their emotional and physical well-being as I do my own,” Stewart said in a statement.

“Just as CBD can support human wellness, it’s been shown to improve the quality of life for pets as well,” she added.

Stewart’s line will include soft chews marketed under three different categories — wellness, calm and mobility — ranging between $19.99 and $22.99 depending on the formula and size of the dog.

The products will be available on Canopy’s e-commerce Web sites and on Franchise Group’s The Vitamin Shoppe Web site next month.

The market for pet CBD products is expected to reach sales of about $400 million in 2027 from just $37.4 million last year, according to a report released by Grand View Research Inc in August.

Tilray stock soars 10% after company tapped to provide medical cannabis in French study – CNBC

Warning: sprintf(): Too few arguments in /var/www/ on line 319

A worker inspects cannabis plants inside the grow room at the Aphria Inc. Diamond facility in Leamington, Ontario, Canada, on Wednesday, Jan. 13, 2021. Tilray Inc. and Aphria Inc. agreed to combine their operations, forming a new giant in the fast-growing cannabis industry.

Annie Sakkab | Bloomberg | Getty Images

Canadian cannabis company Tilray’s stock surged nearly 10% Tuesday after announcing that the French government tapped it to provide cannabis for medical experiments.

The French National Agency for the Safety of Medicines and Health Products will begin the 18- to 24-month study during the first quarter. Tilray’s products will treat patients with neuropathic pain, epilepsy and multiple sclerosis who aren’t getting relief from existing treatments.

Tilray will export the medical-grade cannabis products from its Cantanhede, Portugal facility, which serves as its core research and development site for medical cannabis.

„Today’s announcement marks another milestone for Tilray as we expand operations in Europe,” said Tilray’s Chief Executive Brendan Kennedy.

Tilray shares are down about 2% over the past 12 months, bringing its market value to $2.53 billion.

Want to Start A CBD Company? Follow These Steps to Improve Your Quality – Green Entrepreneur

A compound pharmacist and CBD CEO gives her advice.

Free Book Preview Cannabis Capital

Learn how to get your business funded in the Cannabis economy!

4 min read

Opinions expressed by Entrepreneur contributors are their own.

Never in my life did I expect to become an entrepreneur. For more than 20 years, I worked as a licensed compounding pharmacist. But in 2013, everything changed. I learned about CBD when I was introduced to it by my friend and talented entrepreneur, Arby Barroso, who struggled with health issues. He thought CBD could help, so I started making simple CBD oils and topicals for Arby and my friends and family. 

I was thrilled to see how much health and happiness it brought to their lives. It was incredibly fulfilling to use my expertise to create products from scratch and then see their impact. As word of mouth spread, I knew I had to leave my previous career behind and launch Green Roads.  

There were very few CBD companies in existence at the time and no roadmaps on how to start one. My background as a pharmacist guided my decision-making in those early days. It forced me to put the patient (i.e. customer) first and focus relentlessly on product quality, efficacy, and consistency—even at the expense of profit.  

Today, launching a CBD company is relatively easy. Dozens of manufacturers are ready to provide finished goods to any entrepreneur with a logo and a label. Somebody with any background can get into the CBD business, and there are now more than two thousand CBD brands means that many novices have jumped in. 

Still, if you’re serious about doing what’s best for your customer, I believe products should meet certain standards of quality. Here are a few quality control processes that represent the best practices of how a CBD company can make its products.

Related: 9 Money-Saving Tips for Starting Your Own CBD Company

Know your sources

All of our CBD and other hemp-derived ingredients come from American-farmed hemp plants with certificates of analysis. These certificates show that the hemp extracts do not contain unsafe pesticides or contaminants like heavy metals. Hemp plants have a sponge-like quality. They’ll draw up whatever elements are in the soil, including those nobody would want to consume. That’s why I insist on this sourcing and certificates.

Create proprietary formulations

CBD has had an explosion in popularity. That means countless brands that want a slice of the pie slap their logo on a boilerplate oil or topical cream from an industrial manufacturer. The difference between many of them is only label-deep. As a pharmacist, I had a vision of CBD oil that set a new bar in taste, effect, and mouthfeel. I refined the recipe over and over again until I got there. I didn’t want to create a CBD oil that was curdling, bitter, and like, “taking your medicine.” I believe our proprietary CBD oil is a premium wellness experience, but even brands who aren’t manufacturing their oils should keep pressuring their manufacturer to improve the customer experience. 

Set strict standards

As an entrepreneur, your product is everything. Because of my background as a pharmacist, I knew we owed it to our customers to meet the high standards needed to get our facility for making CBD topicals certified as an OTC maker. That means the FDA has certified that our equipment and procedures meet the strict standards to make over-the-counter quality products. The truth is, this is rare in the CBD industry. It’s time-consuming and a challenge, but one we accepted gladly.

Find the right testing lab

Not all lab testing is created equal. My work in laboratories taught me that pay-to-play laboratories and in-house lab testing do exist and are more common than you may want to think. (This amounts to grading your homework!) We have our ingredients and whole finished products tested for quality by an independent laboratory. For the sake of transparency, we put a QR code leading to the results on every package to give our customers peace of mind.

Related: It’s High Time To Clean Up The CBD Industry

Protect the customer

Our company’s mission is to help each person find the healthiest version of themselves through the power of plants. We have never treated CBD as a fad, always as a wellness product. I believe that more brands need to adopt this mindset for the industry to gain greater acceptance among consumers. Real third-party laboratory testing, proprietary formulations, and American-farmed hemp are all about protecting consumers, and spreading awareness, understanding, and a greater acceptance of CBD and hemp overall.

What Is Delta-8 THC? – Green Entrepreneur

The milder form of THC is gaining popularity among cannabis consumers, but some legal kinks may still have to get worked out.

Free Book Preview Cannabis Capital

Learn how to get your business funded in the Cannabis economy!

3 min read

Opinions expressed by Entrepreneur contributors are their own.

Even those with a passing interest in cannabis know that THC is the plant compound that gives you the high feeling. Less may understand that the THC compound most commonly found in cannabis plants in the United States is called Delta-9 THC, and it has an analog named Delta-8 THC.

Delta-8 THC has become popular with some consumers because it promises the health benefits of cannabis but with a smoother high and less risk of feeling anxious or paranoid. In a way, it fits somewhere between Delta-9 THC and CBD, which contains no THC.

Delta-8 THC is also growing in popularity, much like CBD has done in the past two years. Benzinga listed a Delta-8 product as one of the notable new cannabis products in December 2020.

Related: Why Does Everyone Keep Talking About Terpenes?

What is Delta-8?

Delta-8 THC is not created through cannabinoid-synthesizing enzymes within the cannabis plant, as are many of the 100 different cannabinoids in cannabis. Rather, it occurs after Delta-9 THC is stored for a time and starts to degrade.

Delta-8 THC is considered a minor cannabidiol. The National Cancer Institute reports that it „exhibits a lower psychotropic potency than Delta-9-THC, the primary form of THC found in cannabis.” The institute also lists many of the properties of Delta-8 THC, including „antiemetic, anxiolytic, appetite-stimulating, analgesic, and neuroprotective.”

According to Discover magazine, manufacturers have discovered that Delta-8 THC is more „shelf-stable” than Delta-9, making it a better fit for use in prescription drugs. The magazine reports that because most cannabis plants produce only small amounts of Delta-8, getting a usable amount requires processing and refinement.

Peter Grinspoon, a primary care physician at Harvard Medical School and a board member of Doctors For Cannabis Regulation, told Discover that there’s a difference between Delta-9 and Delta-8. „People report [Delta-8] as being less anxiety-provoking, less sedating, and a little more clear-headed than THC,” Grinspoon said. 

He especially noted the potential use in medicine for older people and children who want „less confusion and spaciness or stoned ness or whatever you want to call it.”

RELATED: THCA And THC: What’s The Difference?

Is it legal?

Search the legality of Delta-8, and you will find a wide variety of opinions, some masquerading as facts. The truth is a bit complicated and mired in bureaucratic process and legal language.

Delta-9 THC is illegal at the federal level. One could say it’s the reason cannabis is illegal at the federal level. However, federal law didn’t directly address Delta-8 until the summer of 2020, when the Drug Enforcement Administration updated its language and added it to the list of illegal compounds derived from cannabis, according to Discover.

However, the 2018 Farm Bill made hemp legal, and much of the Delta-8 used in products on the market comes from hemp. Manufacturers have taken that to mean their product is legal. But the federal government has reopened the public comments period on legalizing hemp, which could lead to changes that may impact Delta-8 THC. At the moment, no one knows for sure what may happen.

According to Discover, many in the industry are waiting to see what changes, if any, occur. In the meantime, it’s worth the time for every cannabis entrepreneur and consumer to learn all they can about what could become the next big thing in cannabis.

To stay up to date on the latest marijuana-related news, make sure to like on Facebook

What’s Next For Cannabis Marketing? – Benzinga

This article by Alex Halperin was originally published on WeedWeek, and appears here with permission.

In cannabis, marketing is everything.

With hundreds of companies selling relatively undifferentiated products, the race to dominate the industry can be understood largely in terms of who develops the deepest brand loyalty and exploits it most effectively. For operators, this includes everything from how they package product and sync their brand with their customers values, to tracking buyer sentiment before, during and after purchases. 

This week the Cannabis Marketing Association hosted a series of TED-style talks on the future of branding the plant. Here are a few key insights:

Michael Brooks, Senior Marketing Strategist, Blue Dream Social

Brooks says the industry needs to understand how Facebook and Google are changing how we shop, despite the internet giants’ unwillingness to work with cannabis companies.

  • He called Google Maps a “super app” for the restaurant industry in that customers can use it for everything from “search and discovery” through reservations and payments. This is all the more remarkable since “six months ago we didn’t know restaurants were an e-commerce product.”
  • Within three years, he said, smart devices power by Google will initiate discussions and purchases based on past behavior. Expect Google to say, “Hello Michael, happy taco Tuesday. Would you like me to make reservations at La Hacienda?” The same could apply to topping off your stash.
  • Facebook’s strategy is about building “the shopping mall of the future,” essentially a way small businesses can sell to customers directly through Instagram. Facebook’s recent purchase of CRM system Kustomer will enable businesses to, for example, import commenters to the top of their sales funnel.   
  • Brooks recommends that companies “flood the zone with content.” But with big tech under unprecedented scrutiny, he said PotCos need to know and understand each platforms terms of service to avoid getting booted.
  • He predicted big tech won’t work with cannabis until federal legalization and then Silicon Valley will pile in very quickly. (NB: It’s worth noting that not all legal products have full access to these platforms, just ask tobacco, alcohol, pharma and porn.) 

Lilli Keinaenen, Packaging designer, Changemaker Creative

Keinaenen’s talk focused on the brand-value of sustainability, or, as she put it, how “green attracts green:”

  • Two out of three consumers consider sustainability when making product choices, Keinaenen said, and they’re willing to pay more for it. How much more is hard to determine. She thought 50 cents would be a reasonable mark-up for a pre-roll.
  • The question then becomes, “How do you measure sustainability?” Factors which can raise a product’s carbon footprint include the lighting used to grow it and how it’s packaged, shipped and stored. 
  • Further complicating matters, objective assessments of products’ carbon footprints haven’t really reached cannabis yet. But she said carbon labelling is coming as is a pollution tax which will force companies to rethink their waste streams.
  • Sustainability is good for business, she added citing food and personal care where sustainable products account for 16% of the market but half of all growth. 
  • “I hope’s the industry doesn’t lose its activist soul,” she said. Can it be “anti-capitalist but still make money?” 

Jason White, Chief Marketing Officer, Curaleaf

White, whose credits include Beats by Dre and LeBron James campaigns for Nike, laid out the multi-state operator’s view of the world. Curaleaf runs 96 stores and sells products in 1,400. It’s brands include Select vapes and Grassroots

  • White argued that by combining marketing and technology, cannabis has the opportunity to “leapfrog” other industries in terms of how they relate to consumers. (As an example, Derek Espinoza, creative director of Arizona edibles company Baked Bros said he’s looking forward to “virtual worlds” where a customer can scan a QR code on their package, put on a headset and have an experience with music and visuals tailored by the brand.)
  • In an industry that “sits on a difficult past,” White said it’s important for brands to have a CSR point of view. He said the killing of George Floyd last year, catalyzed Curaleaf to start building a social equity program, one it will be rolling out soon. He worries that consolidation makes it harder for people of color to join the industry.
  • Curaleaf is in talks with mainstream media brands that are increasingly open to accepting cannabis marketing dollars.
  • Flower now accounts for less than 50% of Curaleaf sales, down from about 75% previously, White said, and he anticipates it will continue to fall to about 25%. Flower, he said, is the toughest product type to brand.
  • He predicted a point where dispensaries will ask customers “What’s ailing you?” and provide scientifically proven products in response. “It will feel like you’re at a CVS but you’re at a Curaleaf.”

Read the original Article on WeedWeek.

Benzinga’s Related Links: 

Quicksilver Scientific provides cutting edge CBD delivery technology for Molson Coors' first US CBD Beverage line – PRNewswire

The U.S. launch of the Veryvell line represents an ambitious leap into a new, non-alcoholic market for Molson Coors and builds upon a successful two-year partnership between Quicksilver and Truss Beverages in Canada. There, the two companies collaborated on development and production of Veryvell’s line of water-soluble cannabis products, which also rely on Quicksilver’s sophisticated delivery technologies to ensure an efficacious and consistent effect. „Quicksilver has proven themselves to be exceptional in terms of quality, efficacy and consistency. As a result, we naturally wanted to extend that partnership to our new U.S. venture, ensuring that these products also provide a best-in-class consumer experience,” said Jane Armstrong Hockman, General Manager, Truss CBD USA.

Quicksilver Scientific applied its extensive experience developing nutraceutical protocols to contribute to Veryvell’s three unique formulations, each intended to deliver an entourage of distinctive benefits. The three blends include „Focus” (grapefruit and tarragon with ginseng and guarana), „Mind & Body” (strawberry and hibiscus with ashwagandha and elderberry) and „Unwind” (blueberry and lavender flavors with ashwagandha and L-Theanine).

Over the past decade, Quicksilver Scientific has perfected the nanoemulsion technology that powers Veryvell hemp-derived CBD beverages. The droplets sheathing the minuscule CBD particles are so small they pass right between cells and enter the bloodstream directly, meaning faster absorption and higher bioavailability in the body. „CBD is not water-soluble, which creates challenges for manufacturers when attempting to mix it into beverages. Our innovative nanoemulsion technology overcomes these challenges by encapsulating nano-sized CBD particles in water-soluble spheres that can be directly added to beverages. The result is a clear, great-tasting product with greater bioavailability, a measure of a compound’s concentration that is absorbed into the body’s bloodstream,” said Dr. Christopher Shade, Ph.D., Founder & CEO of Quicksilver Scientific. Their microscopic size also provides greater transparency in appearance, which is key to beverage applications and stands in direct contrast to the hazy or cloudy appearance of competing emulsions currently being used in the cannabis beverage market.

„The marketplace is saturated with a fairly homogeneous product offering. The Veryvell range, resulting from a highly productive and stimulating collaboration between Quicksilver Scientific and Truss Beverage, is a testament to the real potential for experiential and quality innovation within the non-alcoholic beverage industry,” said Jason Dyer, President, Quicksilver Scientific. „Innovation is what we do at Quicksilver Scientific, and we look forward to expanding our capabilities through future opportunities and challenges with partners like Truss. In doing so, we expect to disrupt and drive the category with products that deliver a more effective, consistent and predictable experience for consumers.”

Quicksilver Scientific’s role in the partnership benefits from the recent addition of David Durkee, Ph.D., as Vice President of New Ventures at Quicksilver. Durkee came to Quicksilver from Molson Coors, where he spent nearly a decade in a wide range of roles, including global product development.

„Combining Quicksilver’s technology and deep knowledge of nutraceuticals with Truss CBD USA’s expertise in manufacturing, logistics and marketing will allow us to elevate Veryvell hemp-derived CBD beverages, demonstrating what the hemp-derived CBD beverage market is capable of,” Durkee said.

For more information or to schedule an interview with Quicksilver Scientific, please contact Shawna Seldon McGregor at 917-971-7852 or [email protected].  

Quicksilver Scientific®: Powering Natural Health

Quicksilver Scientific, Inc. is a leading manufacturer of nutritional supplements featuring proprietary enhanced delivery systems.  The company’s advanced liposomal supplements are highly bioavailable and support vital health functions from absorption of essential vitamins to the elimination of ubiquitous toxins, enabling consumers to achieve their genetic potential. Located in Louisville, Colo., Quicksilver Scientific, Inc. is #652 on the 2019 Inc. 5000, ranking #3 among Boulder metro companies. For more information, visit Shop our products.  Learn more about our science on YouTube. Continue the conversation on Facebook, Instagram, Twitter, LinkedIn and Pinterest.

SOURCE Quicksilver Scientific

Related Links

Israeli Cannabis Company Canndoc to Go Public via SPAC – New Cannabis Ventures

Subversive Announces Qualifying Transaction with InterCure, Israel’s Leading and Fastest-Growing Cannabis Company
  • Combined Company will be led by Chairman and Former Prime Minister of Israel Ehud Barak and CEO Alex Rabinovitch
  • InterCure (dba Canndoc) has Doubled Revenues Sequentially in Four of the Last Five Quarters; Growth Plans Include Tripling Retail Footprint in 2021
  • Well-Positioned for Possible Substantial Market Expansion and Further Positive Free Cash Flow Growth in the Event of Adult-Use Cannabis Reform within the Next 24 Months
  • US$65 Million Private Placement to Support Transaction – Satisfies Required Cash to Close
  • Expected Transaction Close in April 2021
  • Listing of Shares on NASDAQ is a Condition of Closing
  • Common Shares Currently Trade on the OTCQX Under the Symbol “SBVRF” and the NEO Under the Symbol “SVX.U”

NEW YORK and TORONTO and HERZLIYA, Israel, Jan. 26, 2021 /PRNewswire/ — Subversive Real Estate Acquisition REIT LP (OTCQX: SBVRF; NEO: SVX.U) (“SVX”), a special purpose acquisition company (SPAC), today announced its qualifying transaction to combine with InterCure Ltd. (dba Canndoc) (TASE: INCR), Israel’s leading cannabis company (the “Transaction”). Canndoc, a wholly owned subsidiary of InterCure Ltd., is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products in pharmacies across the country. With the largest distribution network, significant logistical capabilities, and a lucrative vertically integrated strategy, Canndoc is the fastest-growing and most profitable cannabis company in Israel, with a Q4 2020 expected EBITDA annualized run rate of greater than US$10 million and positive free cash flow. Furthermore, we believe that Canndoc is well-positioned to capitalize on the adult-use market in Israel, which is expected to be legalized in 2021 or 2022.

We are excited to announce today’s qualifying transaction, which, upon closing, will allow our shareholders to participate in the upside of the Israeli cannabis market. Canndoc has been a pioneer, leading the cannabis wave in Israel and capturing significant market share.

Michael Auerbach, Founder of Subversive Capital

Michael Auerbach, Founder of Subversive Capital, added, “We believe Canndoc possesses superior management, an optimized platform, and the brands and partnerships that set the stage for sustained, profitable growth in key medical and adult-use markets in Israel and beyond.” Click here to access Mr. Auerbach’s video message further highlighting Canndoc’s potential and growth outlook.

Canndoc’s Chairman and former Prime Minister of Israel, Ehud Barak, added, “I’m extremely proud of the work we’ve done at InterCure and Canndoc, and I am looking forward to leading this new chapter. As we discover the scientific advantages in cannabis alongside new favorable legislation, the cannabis industry is unleashing its disruptive commercial potential. Israel became famous for its breakthroughs in cannabis research and has now become one of the leading medical cannabis markets in the world. Canndoc has proven its ability to execute a profitable growth strategy as it became the dominant force in Israel. Nowadays, we are well positioned to lead new emerging cannabis markets as legislative reform is spreading around the globe.” Click here for a video message from Mr. Barak.

Canndoc’s Chief Executive Officer, Alex Rabinovitch, added, “We are thrilled to be partnering with Subversive Capital in this transaction. The SPAC structure facilitates our ability to access growth capital in a relatively short timeframe which, in turn, will support new strategic growth initiatives and drive shareholder value.”

Canndoc Investment Highlights

  • Proven Business Model The most profitable company in Israel’s growing legal cannabis market with a Q4 2020 expected EBITDA annualized run rate of greater than US$10 million and positive free cash flow
  • First Mover Advantage  Significant share of medical market, which grew 40% in 2020; First company to import medical grade cannabis to Israel; Positioned to capitalize on the legalization of recreational cannabis
  • Progressive Operational Platform Highly profitable, vertically integrated medical cannabis platform
  • Key Partnerships – Canndoc’s exclusive partnerships with leading cannabis brands and suppliers include Cookies, Charlotte’s Web, Aphria, Tilray, Organigram, and more
  • Robust Balance Sheet to Support Expansion Cash to drive significant expansion organically and through strategic M&A; Expected expansion of cultivation to over 90 tons per year; Expected to open four additional pharmacies in 2021
  • Experienced Management Team Following the closing of the Transaction, Canndoc will continue to be led by its experienced executive team with deep knowledge of the cannabis industry, and operational expertise in the agriculture technology and pharmaceutical industries:
    • Alex Rabinovitch, Chief Executive Officer
    • Amos Cohen, Chief Financial Officer
    • Rami Levy, Chief Operating Officer
    • Moshe Gavrilov, Chief Marketing Officer
  • Board of Directors and Medical Advisory Board is expected to include:
    • Ehud Barak, former Prime Minister of Israel to serve as Chairman
    • Michael Auerbach, Founder, Subversive Capital
    • Prof. Zvi Bentwich, MD, PHD, Professor of Microbiology, Immunology and Genetics, and Head of the Center for Emerging Tropical Diseases & Aids, Ben Gurion University
    • Prof. Eitan Friedman, Dir. and Founder Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center

SVX has also announced a US$65 million private placement, pursuant to which it will issue 6.5 million units at a price of US$10.00 per unit immediately prior to, and conditional on, completion of the Transaction (the “Private Placement”). The proceeds of the Private Placement are intended to be used in connection with the Transaction and to fund the growth of Canndoc following closing. Based on sources and uses of capital, SVX will have sufficient cash to satisfy the Transaction’s cash closing condition.

It is a condition to closing that, upon closing, the combined company will commence trading on Nasdaq, which listing will be subject to approval from the exchange, and trade on the Tel Aviv Stock Exchange. Further details regarding the post-closing ticker symbol will be provided in advance of closing.

SVX has filed today an investor presentation which describes Canndoc’s business in more detail. Pursuant to the applicable rules, SVX will file with the Canadian securities regulatory authorities of each of the provinces and territories of Canada, except Quebec, a non-offering prospectus containing disclosure regarding the Transaction and InterCure assuming completion of the Transaction.

Transaction Terms and Conditions

  • InterCure valued at US$300.0 million
  • US$225.0 million of proceeds from funds in escrow (assuming no redemptions)
  • PIPE of US$65.0 million to support transaction satisfies cash required for closing

Completion of the Transaction, which is expected in April 2021, remains subject to the satisfaction or waiver of certain customary conditions including, among other things, (a) requisite shareholder and regulatory approvals and (b) approval to list the shares of the combined company on Nasdaq.

This press release is not an offer of securities for sale in the United States, and the securities referred to herein may not be offered or sold in the United States absent registration or an exemption from registration. The securities have not been and will not be registered under the United States Securities Act of 1933.

How to Invest

To invest in SVX, investors may buy or sell shares through their usual investment platform or brokerage. Today, U.S. investors can buy and sell OTCQX securities under the ticker symbol “SBVRF” and Canadian investors can buy and sell through the NEO Exchange under the ticker symbol “SVX.U.” It is a condition to closing that shares of the combined company to commence trading on Nasdaq on closing, and the shares are expected to continue to trade on the Tel Aviv Stock Exchange under the symbol “INCR.” SVX anticipates that the Transaction will close in April 2021.

For more information, visit


Canaccord Genuity Corp. and Cowen Inc. served as financial advisors to SVX. Goodmans LLP, Paul Hastings LLP and Balter, Guth, Aloni│Ne’eman, Keynan│Granot acted as legal counsel to SVX. DTKG&G Co. served as legal counsel to InterCure Ltd.

About SVX

SVX, is a special purpose acquisition corporation established under the laws of the Province of British Columbia for the purpose of effecting, directly or indirectly, a qualifying transaction within a specified period of time. Founded by Michael Auerbach and Leland Hensch, SVX is dedicated to investing in radical companies whose core missions subvert the status quo.

About Subversive Capital

Subversive Capital is a leading investment firm dedicated to investing in radical companies whose core missions subvert the status quo. With over 10 years of experience in the global cannabis industry, Subversive Capital has lead investors in some of the most successful transactions in the industry including the recent launch and closing transaction of Subversive Capital Acquisition Corp. to form The Parent Company (NEO: GRAM.U;OTCQX: GRAMF).

For more information, visit

About InterCure and Canndoc

InterCure (TASE: INCR) is the first public company on the Tel Aviv Stock Exchange to hold a valid and permanent license for the medical cannabis value chain through its 100% ownership in Canndoc. Canndoc is a GMP medical cannabis producer. Licensed by the Israeli Ministry of Health since 2008, Canndoc is a leading pioneer in the research, cultivation, production, and distribution of pharma-grade cannabis-based products to patients, hospitals, pharmacies, research and governmental organizations.

Through its strategic exclusive collaboration with world leaders, distribution agreement with SLE (100% owned by Teva Pharmaceutical Industry) and long-term sales agreements, Canndoc is well-positioned as a leading and significant player in pharma-grade medical cannabis in Israel, Europe and the United Kingdom.

For more information:


This press release makes reference to certain non-IFRS financial measures. EBITDA, as defined by SVX and InterCure, means earnings before interest, income taxes, depreciation and amortization for a quarter annualized. This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. SVX’s and InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measured used by other entities or in other jurisdictions. SVX and InterCure use this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the company.

Original press release

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter